SML1876

PaPE-1

≥98% (HPLC)

• Synonim(y): (S)-5-(4-Hydroxy-3,5-dimethyl-phenyl)-indan-1-ol
• Wzór empiryczny (zapis Hilla): C₁₇H₁₈O₂
• Numer CAS: 2107327-36-4
• Masa cząsteczkowa: 254.32
• UNSPSC Code: 51111800
• NACRES: NA.77
• MDL number: MFCD30723184
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 25 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O[C@H]1CCC2=C1C=CC(C3=CC(C)=C(O)C(C)=C3)=C2
• InChI: 1S/C17H18O2/c1-10-7-14(8-11(2)17(10)19)12-3-5-15-13(9-12)4-6-16(15)18/h3,5,7-9,16,18-19H,4,6H2,1-2H3/t16-/m0/s1
• InChI key: UCXWFKNKSWDWCD-INIZCTEOSA-N

Opis

Biochem/physiol Actions

PaPE-1 is a "Pathway Preferential Estrogen" that activates the extranuclear signaling pathway without activating the nuclear signaling pathway. PaPE-1 bound 50,000-fold less well to ERα and Erβ estrogen receptors. PaPE-1 activated extranuclear-initiated ER-regulated genes, but showed essentially no activation of nuclear-initiated estrogen receptor (ER) gene targets such as the progesterone receptor. Unlike estradiol (E2), PaPE-1 did not stimulate proliferation of MCF-7 breast cancer cells. Like estradiol, PaPE-1 strongly activated MAPK and mTOR pathway. Instead, it showed preferential estrogen-like activity in non-reproductive (metabolic and vascular) tissues, reducing body weight gain and fat accumulation in ovariectomized mice and accelerating repair of endothelial damage in the vascualture.

PaPE-1 is a "Pathway Preferential Estrogen" that activates the extranuclear signaling pathway without activating the nuclear signaling pathway.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H315,H319
• pcodes: P264 - P280 - P302 + P352 - P305 + P351 + P338 - P332 + P313 - P337 + P313
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3